Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
US5972990 | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Oct, 2016
(7 years ago) | |
US5972990 (Pediatric) | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Apr, 2017
(7 years ago) | |
US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Apr 19, 2024 |
Market Authorisation Date: 14 August, 2002
Treatment: Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction; Treatment of hypertensi...
Dosage: TABLET;ORAL